Exosomes derived from MDR cells induce cetuximab resistance in CRC via PI3K/AKT signaling‑mediated Sox2 and PD‑L1 expression

The anti-EGFR antibody cetuximab is used as a first-line targeted therapeutic drug in colorectal cancer. It has previously been reported that the efficacy of the EGFR antibody cetuximab is limited by the emergence of acquired drug resistance. In our previous study the transmissibility effect of exos...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Zhenzhen, Wang, Ziyuan, Chai, Qiong, Li, Zan, Zhang, Mengjie, Zhang, Yuli, Zhang, Lu, Tang, Qingfeng, Zhu, Huirong, Sui, Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9852420/
https://www.ncbi.nlm.nih.gov/pubmed/36741914
http://dx.doi.org/10.3892/etm.2023.11785

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9852420/
https://www.ncbi.nlm.nih.gov/pubmed/36741914
http://dx.doi.org/10.3892/etm.2023.11785

Ejemplares similares